IFRX•benzinga•
InflaRx's Cash, Cash Equivalents, And Marketable Securities Were €55.2M As Of December 31, 2024, Additional €28.7 Million (~$30M) In Gross Proceeds Subsequently Raised By An Underwritten Public Offering Extending Cash Runway Into 2027
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 20, 2025 by benzinga